These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36242541)

  • 1.
    Wijler LA; Dijk FJ; Quirindongo H; Raats DAE; Dorresteijn B; Furber MJW; May AM; Kranenburg O; van Dijk M
    Oncotarget; 2022 Oct; 13():1094-1108. PubMed ID: 36242541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specialized nutrition improves muscle function and physical activity without affecting chemotherapy efficacy in C26 tumour-bearing mice.
    Wijler LA; Raats DAE; Elias SG; Dijk FJ; Quirindongo H; May AM; Furber MJW; Dorresteijn B; van Dijk M; Kranenburg O
    J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):796-810. PubMed ID: 33956410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
    Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
    J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
    Read JA; Beale PJ; Volker DH; Smith N; Childs A; Clarke SJ
    Support Care Cancer; 2007 Mar; 15(3):301-7. PubMed ID: 17021855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer.
    Yi K; Park SH; Kim DU; Jeon DY; Lee HJ; Song GA; Jo HJ; Baek DH; Han JH; Lee BC
    In Vivo; 2023; 37(4):1751-1759. PubMed ID: 37369516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
    Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
    Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
    Munemoto Y; Kanda M; Oba K; Kim HM; Takemoto H; Denda T; Nagata N; Takano N; Fukunaga M; Kataoka M; Tokunaga Y; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2018 May; 81(5):829-838. PubMed ID: 29508026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
    Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
    Ooft SN; Weeber F; Dijkstra KK; McLean CM; Kaing S; van Werkhoven E; Schipper L; Hoes L; Vis DJ; van de Haar J; Prevoo W; Snaebjornsson P; van der Velden D; Klein M; Chalabi M; Boot H; van Leerdam M; Bloemendal HJ; Beerepoot LV; Wessels L; Cuppen E; Clevers H; Voest EE
    Sci Transl Med; 2019 Oct; 11(513):. PubMed ID: 31597751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.
    Rosati G; Cordio S
    Tumori; 2006; 92(4):290-4. PubMed ID: 17036518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
    Wasserman E; Sutherland W; Cvitkovic E
    Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
    Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
    Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
    Committee of Colorectal Cancer, Chinese Southern Oncology Group
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jun; 24(6):473-479. PubMed ID: 34148311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
    Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.